Your browser is no longer supported. Please, upgrade your browser.
AGN Allergan plc daily Stock Chart
Allergan plc
IndexS&P 500 P/E- EPS (ttm)-8.04 Insider Own0.10% Shs Outstand394.50M Perf Week-3.80%
Market Cap86.34B Forward P/E12.72 EPS next Y17.21 Insider Trans- Shs Float394.46M Perf Month-20.40%
Income-3104.50M PEG- EPS next Q3.04 Inst Own90.30% Short Float1.53% Perf Quarter-22.33%
Sales15.07B P/S5.73 EPS this Y23.00% Inst Trans0.11% Short Ratio1.31 Perf Half Y-23.42%
Book/sh181.65 P/B1.20 EPS next Y20.91% ROA2.30% Target Price297.72 Perf Year-24.07%
Cash/sh2.80 P/C78.11 EPS next 5Y10.33% ROE4.50% 52W Range212.67 - 340.34 Perf YTD-29.97%
Dividend0.20 P/FCF21.10 EPS past 5Y-50.40% ROI-1.30% 52W High-35.70% Beta0.61
Dividend %0.09% Quick Ratio0.90 Sales past 5Y33.40% Gross Margin68.10% 52W Low2.91% ATR7.52
Employees31200 Current Ratio1.00 Sales Q/Q73.80% Oper. Margin-22.10% RSI (14)29.79 Volatility2.16% 4.06%
OptionableYes Debt/Eq0.60 EPS Q/Q42.60% Profit Margin20.90% Rel Volume0.51 Prev Close220.07
ShortableYes LT Debt/Eq0.56 EarningsMay 10 BMO Payout0.00% Avg Volume4.60M Price218.85
Recom1.80 SMA20-6.31% SMA50-17.08% SMA200-24.69% Volume2,325,800 Change-0.55%
Apr-18-16Resumed Goldman Buy $275
Apr-18-16Initiated Guggenheim Neutral
Apr-18-16Downgrade Piper Jaffray Overweight → Neutral $311 → $238
Apr-07-16Resumed Morgan Stanley Overweight $300
Apr-07-16Resumed JP Morgan Overweight
Apr-07-16Reiterated UBS Buy $366 → $300
Apr-07-16Downgrade Susquehanna Positive → Neutral
Apr-06-16Downgrade Mizuho Buy → Neutral $330 → $250
Mar-31-16Reiterated Canaccord Genuity Buy $340 → $320
Feb-23-16Reiterated Mizuho Buy $354 → $330
Feb-23-16Reiterated Deutsche Bank Buy $308 → $339
Feb-19-16Initiated Wells Fargo Outperform
Nov-24-15Reiterated Mizuho Buy $340 → $354
Nov-13-15Reiterated Mizuho Buy $337 → $340
Oct-28-15Reiterated Leerink Partners Outperform $311 → $342
Oct-09-15Initiated Mizuho Buy
Sep-29-15Initiated Nomura Buy
Aug-07-15Reiterated RBC Capital Mkts Outperform $361 → $375
Aug-07-15Reiterated Deutsche Bank Buy $346 → $350
Aug-03-15Resumed JP Morgan Overweight $375 → $400
Apr-28-16 01:28PM  Shareholders criticize Pfizer after scrapped Allergan deal AP
Apr-27-16 04:24PM  Is Allergan On The Prowl For New Deals? at Forbes
07:20AM  Allergan Is About to Enter a Low-Risk Buy Zone at TheStreet
Apr-26-16 11:25AM  Treasury Department Was 'Targeting' Pfizer-Allergan Deal at TheStreet
11:24AM  With New Treasury Department Rules, Is This the End of Tax Inversion Deals? at TheStreet
11:23AM  Tax Inversions: Explaining What They Are, How We Got Here and What's Next at TheStreet
07:55AM  Allergan Presents Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Seattle PR Newswire
07:24AM  Cramer: Papa's Got a Brand New Bag, and Leaves Perrigo Holding the Old One at TheStreet
Apr-25-16 04:05PM  Allergan Breaks Ground on $200 Million Waco Facility Expansion PR Newswire
01:31PM  Is Now the Time to Jump on Allergan? at TheStreet
12:10PM  Jim Cramer Says Investors Should Own Allergan, Shares are Undervalued at TheStreet
11:25AM  Celgene (CELG) Q1 Earnings: What's in Store for the Stock? Zacks
08:51AM  The Morning Download: Allergan CIO Says M&A Helps Pharmaceuticals Giant Drive Down IT Costs at The Wall Street Journal
07:10AM  Goldman Sach's 5 Large-Cap Pharma Stock Favorites Ahead of Earnings at TheStreet
06:41AM  3 top value plays: Pro CNBC
Apr-24-16 01:07PM  Billionaire Dan Loebs Top Picks Register Disappointing Returns at Insider Monkey
Apr-23-16 09:01AM  Valeant Hits Another Big Hedge Fund Yahoo Finance Contributors
Apr-22-16 08:34PM  [$$] Allergan Bags Topokine Therapeutics for Undereye Treatment at The Wall Street Journal
02:00PM  Allergan bags a Boston-based eye bag cream developer for $85M at American City Business Journals
01:05PM  Allergan Acquisitions Jump-Start IT Efficiency at The Wall Street Journal
09:56AM  Allergan Announces Acquisition Of Topokine Therapeutics, Highlights Fat Reduction Development Program Benzinga
09:39AM  3 Stocks We're Ready to Buy Again at Motley Fool
08:35AM  What Weak Earnings At Goldman Sachs And J.P. Morgan Mean For Biotech at Forbes
Apr-21-16 04:30PM  Allergan Acquires Topical Dermatology Company Topokine Therapeutics Adding Non-Invasive Fat Reduction Development Program PR Newswire
10:30AM  8 Latino business founders over $1 million mark at CNBC
10:23AM  A Look at Zach Schreibers Top Picks Ahead of His Ira Sohn Presentation at Insider Monkey
Apr-20-16 10:39AM  3 Value Stocks Near 52-Week Lows Worth Buying at Motley Fool
10:30AM  The Makers of Botox Are Pushing a Cure for Your Double Chin at Bloomberg
09:01AM  Lessons From The Fall Of SUNE And VRX Yahoo Finance Contributors
07:30AM  Allergan to Host First Quarter 2016 Earnings Conference Call and Webcast PR Newswire
Apr-19-16 02:24PM  3 Biggest Challenges Facing Lannett Company Inc. Stock at Motley Fool
12:03PM  Jim Cramer -- Skip GlaxoSmithKline, but Buy Johnson & Johnson at TheStreet
11:45AM  Jim Cramer Likes Johnson & Johnson, Allergan in the Pharma Sector at TheStreet
11:34AM  Synergy Pharmaceuticals Soars After FDA Filing Accepted at TheStreet
Apr-18-16 12:30PM  2 Potential Targets of Allergan's Cash Influx
06:48AM  Coverage initiated on Allergan by Guggenheim
Apr-17-16 06:47PM  Barron's Picks And Pans: Ford, Intel, Sealed Air And More
09:00AM  Jim Cramer: Pfizer Maintains Strong Growth Profile After Allergan Bust at TheStreet
Apr-16-16 09:01AM  John Hempton: Valeant Is Headed Towards ZERO
Apr-15-16 09:00PM  Watch Out for Soft Economic News; 10 Reasons Hedge Funds Are in Trouble: Best of Kass at TheStreet
07:33PM  Drug manufacturer must pay $125M in health care fraud case
12:30PM  Allergan's Outlook Brightens as Generics Sale Seems on Track
09:08AM  Citigroup beats low expectations
Apr-14-16 04:13PM  ALLERGAN PLC Files SEC form 8-K, Regulation FD Disclosure
11:37AM  Larry Summers: The prospect of Donald Trump being president is the gravest threat to America
10:36AM  Moody's: Strength of Allergan's credit profile will depend on use of cash from divestiture at Moody's
09:12AM  Lew: Rules to block mergers were not retroactive at CNBC
08:00AM  American CryoStem Appoints Nobel Prize Nominee and One of the Leading Stem Cell Experts Vincent C. Giampapa, M.D. to Its Medical and Scientific Advisory Board Marketwired
05:22AM  Politics is killing health-care stocks at MarketWatch
Apr-13-16 04:04PM  The 52-Week Low Club for Wednesday at 24/7 Wall St.
02:53PM  Jim Cramer: What's Going on With Valeant, Allergan? at TheStreet
01:55PM  CIO Voices: Allergan's Sean Lennon Says Never Presume Job Security in a Merger at The Wall Street Journal
01:25PM  Jim Cramer: Pfizer Acting Better Since Broken Allergan Deal at TheStreet
12:15PM  Valeant Stock Flatlines Despite Trio Of Terrible News Events at Forbes
08:00AM  Allergan Announces 10 Presentations on Chronic Migraine, Upper and Lower Limb Spasticity and Alzheimer's Disease at the American Academy of Neurology Meeting in Vancouver PR Newswire
Apr-12-16 05:42PM  Peering Into Allergan's Post-Pfizer Future at Motley Fool
04:04PM  The 52-Week Low Club for Tuesday at 24/7 Wall St.
02:36PM  11 Stocks Hurt By Treasury's New Tax Rules at
12:32PM  What Bill Ackman's Voice Could Mean for the Valeant Board Room
12:21PM  Pfizer Inc's Unspoken Message To Investors: It Was Always About Taxes at Motley Fool
07:25AM  Unpredictable Precedent: Bread, Circuses And The Termination Of Pfizer-Allergan at Forbes
Apr-11-16 07:02PM  Johnson Controls-Tyco Will Sail By New Treasury Rules at The Wall Street Journal
06:04PM  Allergan's Share Price Makes No Sense -- Until You Consider These Two Things at Motley Fool
04:18PM  CP Rail mulls buyback, dividend after dropping Norfolk bid -CEO
04:04PM  The 52-Week Low Club for Monday at 24/7 Wall St.
03:59PM  How Pfizer and Allergan's Merger Got Busted By Washington at Motley Fool
01:11PM  Endo International Tumbles as Insys Expects Weak Painkiller Sales at TheStreet
10:01AM  3 Ways Pfizer Can Improve Shareholder Value Without Allergan at Motley Fool
09:30AM  The Zacks Analyst Blog Highlights: Pfizer, Allergan, Boeing, General Electric and International Business Machines
08:04AM  Drug stocks get shot in arm from busted deal at USA TODAY
08:02AM  [$$] Local politics can turn deal heroes to zeros at Financial Times
01:00AM  Allergan, Tesla and iShares Nasdaq Biotechnology: Doug Kass' Views at TheStreet
12:05AM  [$$] M&A crackdown puts bond investors on edge at Financial Times
Apr-10-16 12:29PM  Have Billionaires Made the Right Call Betting on These Stocks? at Insider Monkey
10:00AM  Allergan Could Buy These Drug Companies Now That the Pfizer Merger Is Scuttled at TheStreet
09:00AM  President Obama's Implicit Message To Taxpayers: 'I Own You' at Forbes
Apr-09-16 12:02PM  Breaking Down Pfizer's Break-Up With Allergan at Motley Fool
12:12AM  [$$] Pfizer: Slim Down to Bulk Up the Stock at The Wall Street Journal
Apr-08-16 09:00PM  Our 'Bizarro' Investment World; The Fed Reveals Nothing: Best of Kass at TheStreet
09:00PM  If Only Banks Were Utilities: Pharma's in the Doghouse: Jim Cramer's Best Blogs at TheStreet
04:32PM  It was a brutal week for some of the world's biggest hedge funds
03:12PM  [$$] Pfizer: Slim Down to Bulk Up the Stock at The Wall Street Journal
02:51PM  If Valeant Sells Bausch & Lomb, Will Allergan Be a Bidder? at
02:25PM  Wall Street's Couch Trip at Bloomberg
01:12PM  [$$] M&A splurge comes home to roost at Financial Times
01:07PM  Jim Cramer: What's Going on Between Business and the U.S. Government? at TheStreet
12:29PM  US government gives M&A bond investors a wake-up call Reuters
12:21PM  Treasury's New Inversion Regs Aren't Just About Inversions at Forbes
10:58AM  Obamas Regulatory Rampage at Fortune
10:10AM  New Tax Inversion Rules to Hurt Investment Banking Income
09:55AM  INVESTMENT FOCUS-Investors favour European drug stocks in spite of M&A crackdown Reuters
07:47AM  [$$] Trevena Stock Could Double to $20 at
07:30AM  Allergan Reinforces Commitment to Anti-Infective Innovation with 20 Abstracts Highlighted at ECCMID 2016 PR Newswire
12:33AM  Allergan Completes Licensing Deal After Pfizer Bid Collapses at The Wall Street Journal
Apr-07-16 09:34PM  Investors stick with Pfizer CEO after Allergan deal scrapped Reuters
07:14PM  Treasury Erects Iron Tax Curtain
07:01PM  Biotech: Breakout or lull? at CNBC
06:33PM  Jim Cramer's 'Mad Money' Recap: Uncle Sam, Back Off Business! at TheStreet
06:25PM  Allergan Struck a $3.3 Billion Alzheimers Drug Deal Right After Its Pfizer Merger Collapsed at Fortune
06:00PM  Cramer: Sanders' attack on biz unprecedented
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. The company offers a portfolio of products that provide treatments for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, and medical aesthetics, as well as dermatology and plastic surgery. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. Allergan plc also distributes generic and branded pharmaceutical products primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physicians' offices. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Parsippany, New Jersey.